A phase 1 dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of cln-619 (Anti-MICA/B antibody) alone and in combination with pembrolizumab in patients with advanced solid tumors.
Year: 2023
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Judy S. Wang, Martin Gutierrez, Drew W. Rasco, Ignacio Melero Bermejo, John D. Powderly, Erika P. Hamilton, Michael Millward, Ana Maria Arance, Rafal Stec, Victor Moreno, Manish Sharma, Iwona A. Lugowska, Mark J. Shackleton, Sophia Frentzas, John Edward Janik, Tracy Liu, Irina Shapiro, Kerry Whalen, Jeffrey Alan Jones, Alexander I. Spira
Institutions: Hackensack Meridian Health, South Texas Accelerated Research Therapeutics, Universidad de Navarra, Carolina BioOncology Institute, Sarah Cannon, Tennessee Oncology, The University of Western Australia, Linear Clinical Research, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Medical University of Warsaw, Hospital Universitario Fundación Jiménez Díaz, Instytut Matki i Dziecka, The Alfred Hospital, Monash University, Cullinan Oncology (United States), Virginia Cancer Specialists
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4379283078